{"page_content": "17\nPTC Therapeutics | 2021 ESG ReportClinical Trials\nPTC has multiple registration-directed clinical trials that hold hope for many rare diseases. \nMany of these will read out in the near term. \nCOVID-19 Duchenne Muscular \nDystrophy\n(nmDMD)Mitochondrial  \nDisease Associated \nSeizures  \n(MDAS)Phenylketonuria  \n(PKU)Friedreich Ataxia  \n(FA)\nData Expected\n1H 2022 2Q 2022 4Q 2022 YE 2022 2Q 2023PTC923 Vatiquinone Vatiquinone US Ataluren Emvododstat\n17WHO WE ARE        OUR ENVIRONMENT       OUR PATIENTS       OUR PEOPLE        OUR CUL TURE & COMMUNITY       ETHICS & COMPLIANCE       \nPTC Therapeutics | 2021 ESG ReportProducts & Pipeline\nPTC has a robust pipeline filled with innovative compounds targeted at the underlying cause of \ndiseases with high unmet medical need.\nFive Registration-Directed Clinical Trials Drives Near-Term Value\n", "metadata": {"source": "NASDAQ_PTCT_2021.pdf", "page": 16, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}